We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Theratechnologies Inc.: Tesamorelin Filed for Marketing Authorization in Argentina
News

Theratechnologies Inc.: Tesamorelin Filed for Marketing Authorization in Argentina

Theratechnologies Inc.: Tesamorelin Filed for Marketing Authorization in Argentina
News

Theratechnologies Inc.: Tesamorelin Filed for Marketing Authorization in Argentina

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Theratechnologies Inc.: Tesamorelin Filed for Marketing Authorization in Argentina"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Theratechnologies Inc. has announced that an affiliate of Sanofi, its commercial partner, has filed a marketing authorization application for tesamorelin in Argentina with the Ministry of Health's National Administration of Drugs, Foods and Medical Technology (ANMAT).

Tesamorelin is proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.

Theratechnologies estimates that there are approximately 13,000 HIV-infected patients suffering from excess abdominal fat in Argentina. Currently, there are no approved treatments available for this condition in South America.

"We are committed to maximizing the commercial potential of tesamorelin and this cannot be done without the efficient filing of regulatory applications in new markets. Through our partner, Sanofi, we are making great progress in this regard and we are very pleased," said Mr. John-Michel T. Huss, President and Chief Executive Officer of Theratechnologies.

"Argentina and Brazil, where an application was also filed, represent important Latin American markets," concluded Mr. Huss.

Theratechnologies signed a distribution and licensing agreement with an affiliate of Sanofi on December 6, 2010, granting them exclusive commercialization rights for tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy in Latin America, Africa and the Middle East.

Additional applications for tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy are currently under review with regulatory agencies in Europe, Brazil, Canada and Israel.

Advertisement